(hydroxyprogesterone caproate injection)
(estradiol transdermal spray)
(Butoconazole Nitrate Vaginal Cream USP, 2%)
Ask the Healthcare Professional
Secured Investor Reporting Site
Research & Development
Update on Ongoing Makena
Contributing 61.1% of KV revenues in Fiscal 2008, ETHEX, KV’s generic/non-branded marketing subsidiary, utilizes KV Pharmaceutical’s patented drug delivery technologies and specialty manufacturing expertise to target niche products facing limited competition. Marketing over 100 products with almost 60% identified as leading products in their respective generic categories, according to independent research data, we believe ETHEX achieves significantly higher gross margins than its primary competitors. ETHEX continues to leverage its core competencies as well as its value-added marketing successes to produce consistent, solid growth in a highly competitive and price sensitive marketplace.
to learn more about ETHEX Corporation.
©2014 KV Pharmaceutical Company. All Rights Reserved.